Advertisement

Lymph node dissections in cutaneous malignancy: Where are we now? A review of 10 years’ experience at a tertiary centre

Published:April 19, 2021DOI:https://doi.org/10.1016/j.bjps.2021.03.115

      Summary

      The surgical management of cutaneous malignancies has evolved over recent years with the introduction of novel medical therapies and an increasing emphasis upon early adjuvant systemic therapy. As such, completion lymph node dissection (cLND) is now no longer recommended following a positive sentinel lymph node biopsy (SLNB) in melanoma. We evaluated our ten-year practice at a regional tertiary centre, assessing the change in lymph node dissection (LND) caseload volume, anatomical distribution, and indication for the procedure.
      A retrospective search was carried out of all LNDs performed by the Plastic Surgery department at Cambridge University Hospitals NHS Trust, UK from 1 January 2010 to 31 December 2019. Case notes were retrospectively analysed for each procedure, with the site and pathology recorded.
      A total of 491 LNDs were performed over the 10-year period. Surgical volume peaked in 2015 with 67 cases, followed by a decline to 41 cases in 2019. The number of neck dissections increased over the decade, as well as the proportion of cases due to macroscopic nodal disease. We sub-analysed the number of LNDs in three contiguous 18-month intervals, corresponding to changes in practice due to evidence from the DeCOG and MSLT-II Trials. We found a 41.67% reduction in LNDs caseload between July 2018-Dec 2019, compared to a similar period prior to trial evidence (July 2015-Dec 2016) (p=0.0.14).
      In summary, the surgical volume of LNDs has decreased significantly since 2018, reflecting emerging evidence and changes to national guidelines. This will require ongoing monitoring for workforce planning and surgical training.

      Keywords

      To read this article in full you will need to make a payment

      References

      1. Research C. Melanoma skin cancer statistics | Cancer Research UK. Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer%0Ahttps://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer#heading-Zero.%0Ah. Published 2020. Accessed June 6, 2020.

      2. Non-melanoma skin cancer statistics | Cancer Research UK. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/non-melanoma-skin-cancer#heading-One. Accessed January 18, 2021.

        • Apalla Z
        • Nashan D
        • Weller RB
        • Castellsagué X.
        Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches.
        Dermatol Ther (Heidelb). 2017; 7: 5-19https://doi.org/10.1007/s13555-016-0165-y
        • Guggenheim MM
        • Hug U
        • Jung FJ
        • et al.
        Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma.
        Ann Surg. 2008; 247: 687-693https://doi.org/10.1097/SLA.0b013e318161312a
        • Veness MJ
        • Palme CE
        • Smith M
        • Cakir B
        • Morgan GJ
        • Kalnins I.
        Cutaneous head and neck squamous cell carcinoma metastatic to cervical lymph nodes (nonparotid): A better outcome with surgery and adjuvant radiotherapy.
        Laryngoscope. 2003; 113: 1827-1833https://doi.org/10.1097/00005537-200310000-00031
      3. NICE. Melanoma: Assessment and Management NICE Guideline NG14 - Full Guideline.; 2015. www.nice.org.uk/guidance/ng 14%0Ahttp://www.ncbi.nlm.nih.gov/pubmed/26334080. Accessed January 30, 2021.

        • Masoud SJ
        • Perone JA
        • Farrow NE
        • Mosca PJ
        • Tyler DS
        • Beasley GM.
        Sentinel Lymph Node Biopsy and Completion Lymph Node Dissection for Melanoma.
        Curr Treat Options Oncol. 2018; 19: 55https://doi.org/10.1007/s11864-018-0575-4
        • Morton DL
        • Cochran AJ
        • Thompson JF
        • et al.
        Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial.
        Annals of Surgery. 2005; 242 (VolLippincott, Williams, and Wilkins): 302-313https://doi.org/10.1097/01.sla.0000181092.50141.fa
        • Faries MB
        • Thompson JF
        • Cochran AJ
        • et al.
        Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
        N Engl J Med. 2017; 376: 2211-2222https://doi.org/10.1056/nejmoa1613210
        • Bello DM
        • Faries MB.
        The Landmark Series: MSLT-1, MSLT-2 and DeCOG (Management of Lymph Nodes).
        Ann Surg Oncol. 2020; 27: 15-21https://doi.org/10.1245/s10434-019-07830-w
        • Leiter U
        • Stadler R
        • Mauch C
        • et al.
        Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.
        Lancet Oncol. 2016; 17: 757-767https://doi.org/10.1016/S1470-2045(16)00141-8
        • Faries MB
        • Thompson JF
        • Cochran AJ
        • et al.
        Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
        N Engl J Med. 2017; 376: 2211-2222https://doi.org/10.1056/nejmoa1613210
        • Peach H
        • Board R
        • Cook M
        • et al.
        Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement.
        J Plast Reconstr Aesthetic Surg. 2020; 73: 36-42https://doi.org/10.1016/j.bjps.2019.06.020
        • Misky AT
        • Sadr AH
        • Nikkhah D.
        Impact of MSLT-II on lymph node clearance surgery in a tertiary plastic surgery centre.
        J Plast Reconstr Aesthetic Surg. 2020; 73: 1897-1916https://doi.org/10.1016/j.bjps.2020.05.045
        • Silberstein E
        • Sofrin E
        • Bogdanov-Berezovsky A
        • Nash M
        • Segal N.
        Lymph node metastasis in cutaneous head and neck squamous cell carcinoma.
        Dermatologic Surg. 2015; 41: 1126-1129https://doi.org/10.1097/DSS.0000000000000488
        • Lebbe C
        • Becker JC
        • Grob JJ
        • et al.
        Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline.
        Eur J Cancer. 2015; 51: 2396-2403https://doi.org/10.1016/j.ejca.2015.06.131
        • Keohane SG
        • Proby CM
        • Newlands C
        • et al.
        The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K.
        Br J Dermatol. 2018; 179: 824-828https://doi.org/10.1111/bjd.16892
        • von Elm E
        • Altman DG
        • Egger M
        • Pocock SJ
        • Gøtzsche PC
        • Vandenbroucke JP.
        The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.
        J Clin Epidemiol. 2008; 61: 344-349https://doi.org/10.1016/j.jclinepi.2007.11.008
        • Office for National Statistics
        Clinical Commissioning Group Population Estimates, Mid-2011 (Census Based).
        Dataset. 2021; (77-318167. Published 2013. Accessed February 9)
        • UK CR
        Worldwide cancer incidence statistics.
        Cancer Research UK. 2021; (Published 2018. Accessed February 9)
        • Marsden JR
        • Newton-Bishop JA
        • Burrows L
        • et al.
        Revised UK guidelines for the management of cutaneous melanoma 2010.
        J Plast Reconstr Aesthetic Surg. 2010; 63: 1401-1419https://doi.org/10.1016/j.bjps.2010.07.006
      4. JCST. Certification Guidelines for Plastic Surgery. 2017;(July):1-3.

        • Von Schuckmann LA
        • Hughes MCB
        • Ghiasvand R
        • et al.
        Risk of Melanoma Recurrence after Diagnosis of a High-Risk Primary Tumor.
        JAMA Dermatology. 2019; 155: 688-693https://doi.org/10.1001/jamadermatol.2019.0440
        • National Institute for Health and Care Excellence
        Technology appraisal guidance [TA592] - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma.
        WwwNiceOrgUk. 2019; (Accessed February 9, 2021)